1
|
Matsumura F, Sakamoto T, Kai H, Usui T, Kawanishi K, Matsuoka R, Ishitsuka K, Makishima K, Suma S, Maruyama Y, Kato T, Kurita N, Hattori K, Suehara Y, Nishikii H, Obara N, Usui J, Matsubara D, Yamagata K, Sakata-Yanagimoto M. A Case of Multiple Myeloma in a Patient with Birt-Hogg-Dube Syndrome. Intern Med 2025:4985-24. [PMID: 40090716 DOI: 10.2169/internalmedicine.4985-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/18/2025] Open
Abstract
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant disease caused by germline folliculin (FLCN) mutations and it is characterized by skin folliculomas, pulmonary cysts, and renal cell carcinomas (RCC). We herein report the first case of a female patient with BHDS who was diagnosed with multiple myeloma. Daratumumab-based treatment was effective, and the patient remained responsive for over three years. Whole-exome sequencing confirmed an FLCN germline mutation and nine somatic mutations, including an MPDZ mutation, which is a component of the tumor-suppressive Hippo-YAP pathway. Considering the reported association between the Hippo-YAP pathway and RCC with BHDS, an MPDZ mutation may contribute to carcinogenesis in patients with BHDS.
Collapse
Affiliation(s)
| | - Tatsuhiro Sakamoto
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Hirayasu Kai
- Ibaraki Clinical Education and Training Center, Institute of Medicine, University of Tsukuba Hospital, Japan
- Ibaraki Prefectural Central Hospital, Japan
| | - Toshiaki Usui
- Department of Nephrology, Institute of Medicine, University of Tsukuba, Japan
| | - Kunio Kawanishi
- Department of Experimental Pathology, Institute of Medicine, University of Tsukuba, Japan
- Department of Anatomy, Showa Medical University, Japan
| | - Ryota Matsuoka
- Department of Diagnostic Pathology, Institute of Medicine, University of Tsukuba, Japan
| | | | | | - Sakurako Suma
- Department of Hematology, University of Tsukuba Hospital, Japan
| | - Yumiko Maruyama
- Department of Hematology, University of Tsukuba Hospital, Japan
| | - Takayasu Kato
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Naoki Kurita
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Keiichiro Hattori
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Yasuhito Suehara
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Hidekazu Nishikii
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Naoshi Obara
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
| | - Joichi Usui
- Department of Nephrology, Institute of Medicine, University of Tsukuba, Japan
| | - Daisuke Matsubara
- Department of Diagnostic Pathology, Institute of Medicine, University of Tsukuba, Japan
| | - Kunihiro Yamagata
- Department of Nephrology, Institute of Medicine, University of Tsukuba, Japan
| | - Mamiko Sakata-Yanagimoto
- Department of Hematology, Institute of Medicine, University of Tsukuba, Japan
- Division of Advanced Hemato-Oncology, Transborder Medical Research Center, Japan
| |
Collapse
|
2
|
Zhao Q, Li F, Li J, Xia Y, Wang J, Chen L. An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma. Clin Exp Med 2024; 24:16. [PMID: 38280104 PMCID: PMC10821848 DOI: 10.1007/s10238-023-01277-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 11/25/2023] [Indexed: 01/29/2024]
Abstract
Multiple myeloma (MM) is a highly heterogeneous and incurable disease. Inflammation plays a vital role in cancer genesis and progression. However, the relationship between inflammatory response-related genes (IRRGs) and the prognosis of MM patients remains unknown. We constructed a IRRGs prognosis model by least absolute shrinkage and selection operator regression analysis. Moreover, clinical multivariate regression was performed to identify clinical implications. Gene set enrichment analysis was implemented to conduct its biological properties. CIBERSORT deconvolution algorithm was utilized to calculate the immune cell infiltration in different risk groups. The flow cytometry was utilized to perform protein expression of prognostic gene. A Six-IRRGs (VCAM1, RGS1, KIT, CD81, BLNK, and BIRC3) prognostic risk model was successfully constructed and validated. The risk model was an independent predictor for overall survival. Enrichment analysis revealed autophagy and PI3K-Akt signaling pathways were enriched in the high-risk group. Furthermore, we found CD81 widely impacted on the infiltration of immune cells, especially on monocytes and macrophages2. At last, the role of CD81 in MM was confirmed to be an adverse prognostic factor in clinical. Our study explores the potential application value of IRRGs in MM. These findings may provide new insights into the treatment for MM patients.
Collapse
Affiliation(s)
- Qian Zhao
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China
- Department of Hematology, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, China
| | - Feng Li
- Department of Hematology, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, China
| | - Jing Li
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China
| | - Yuan Xia
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China
| | - Jing Wang
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China
| | - Lijuan Chen
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210003, China.
| |
Collapse
|